News & Updates

Response to first-line treatment tied to longer survival in HER2-positive breast cancer
Response to first-line treatment tied to longer survival in HER2-positive breast cancer
30 Mar 2024

Patients with de novo human epidermal growth receptor 2 (HER2)-positive metastatic breast cancer (MBC) who show radiographic response to first-line HER2-directed therapy are more likely to achieve long-term survival, suggests a recent study.

Response to first-line treatment tied to longer survival in HER2-positive breast cancer
30 Mar 2024